Topical Therapies for Onychomycosis

Wang, Casey; Canavan, Theresa; Elewski, Boni E.

doi:10.1002/9781119226512.ch11

Cited by 1 publication

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its incidence is rising due to the ageing population (ONC prevalence increases with age, affecting 20% to 50% of individuals over 60 years of age) [ 1 , 2 , 3 , 4 , 5 ] and increasing numbers of diabetic patients, who are 2.5 times more likely to develop ONC [ 2 , 5 , 6 , 7 ]. The challenges found in the development of efficacious topical treatments for onychomycosis have stimulated research on new formulations and enhancement approaches that may lead to more efficient topical medicines [ 8 , 9 , 10 , 11 ]. ONC topical treatments are time-consuming, requiring daily or weekly applications for up to one year [ 12 ], which leads to low compliance and treatment failure [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

New Formulation–Microporation Combination Approaches to Delivering Ciclopirox across Human Nails

Kishishita,

de Almeida Perez Pimenta,

Cerqueira Macedo

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Topical treatments for onychomycosis are of interest to those seeking to avoid systemic drug interactions and to improve systemic safety. This work aimed to develop aqueous-based, simple, and cost-effective vehicles that provide high solubility for ciclopirox and enable the delivery of an active through channels created by nail microporation. Following solubility tests, aqueous gels and thermogels based on hydroxypropylmethylcellulose and poloxamer 407, respectively, were loaded with 8% and 16% ciclopirox. Their performance was then compared to the marketed lacquer Micolamina® in in vitro release tests with artificial membranes and in in vitro permeation tests with human nail clippings with and without poration. Finally, a microbiological assay compared the best gel formulations and the reference product. Little correlation was observed between the in vitro release and the permeation data, and the drug release was highly membrane-dependent. Ciclopirox nail retention in single-dose, porated nails tests was larger than in daily-dosing, non-porated nail conditions. The series of new gel and thermogel vehicles delivered ciclopirox more effectively than Micolamina® in single-dose, porated nail experiments. The inhibition of Trichophyton rubrum activity was significantly increased with microporated nails when the gel formulations were applied but not with Micolamina®. Overall, the results suggest that the new vehicles could be successfully combined with nail microporation to improve the drug delivery and efficacy of topical antifungal medication while reducing the dosing frequency, facilitating patients’ adherence.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Figure11. Mean (± SD, n = 4) percentage inhibition of T. rubrum activity after treatment of porated and non-porated nails with 16% CPO gels, GH6 and GH6GK, and 8% CPO Micolamina ® .…”

mentioning

confidence: 99%